

# Cancer Combination Therapies

The 3rd AstraZeneca – MedImmune – CRUK Cambridge Centre Symposium

25th – 26th September 2017, Churchill College, Cambridge

This two-day symposium is an opportunity for scientists from AstraZeneca, MedImmune and the Cambridge scientific community to discuss and present cutting-edge research focussed on combinations, spanning preclinical, translational and clinical research. The symposium agenda is designed to enable you to network, discuss key research developments and identify new opportunities for collaboration.

**Hosts:** **Susan Galbraith**, VP Head, AZ Oncology IMed  
**Tony Johnson**, VP Head, AZ Early Clinical Development  
**Richard Gilbertson**, Director, CRUK Cambridge Centre

## Key cancer science topics to be covered:

- Preclinical evaluation and screening for combinations
- Early phase design, scheduling and toxicity considerations for combinations
- Combinations in DDR and radiotherapy
- Combinations with immunotherapy
- Targeted therapy combinations
- Translational biomarkers and ctDNA for combinations

Join us to  
unlock the  
power of  
combinations

## Target audience

PhD students and PostDocs through to established Group Leaders actively engaged in cancer research.

## Application process

If you are interested in attending the symposium, please apply by 26th May 2017 via the registration link on the CRUK Cambridge Centre website using the link below.

[Apply Here](#)

Space will be limited at the symposium, therefore preference will be given to those who would like to present either a short (10 min) talk or poster. We would therefore encourage you to submit an abstract (maximum of 250 words) for either a talk or poster, when registering your interest.

For more information on the symposium please contact: [Jennifer.Parkinson@astrazeneca.com](mailto:Jennifer.Parkinson@astrazeneca.com)



CANCER  
RESEARCH  
UK

CAMBRIDGE  
CENTRE



Cambridge University Hospitals   
NHS Foundation Trust

